REDWOOD CITY, Calif., Aug. 4, 2011 /PRNewswire/ — Genomic Health, Inc.
GHDX) today announced that Dean Schorno, Genomic Health’s Chief
Financial Officer, will present at the 31st Annual Canaccord
Genuity Growth Conference in Boston on Thursday, August 11, 2011 at
11:30 a.m. Eastern Time (ET).
To access the live and subsequently archived webcast of the
presentation, visit the Investor Relations section of Genomic
Health’s website at http://investor.genomichealth.com.
Please connect to the website at least 15 minutes prior to
the beginning of the presentation to allow for any necessary
software downloads. An archived replay will be available for
three months beginning 24 hours after the live presentation.
About Genomic Health
Genomic Health, Inc. (NASDAQ:
GHDX) is a molecular diagnostics company focused on the global
development and commercialization of genomic-based clinical
laboratory services that analyze the underlying biology of cancer
allowing physicians and patients to make individualized treatment
decisions. Its lead product, the Oncotype DX®
breast cancer test, has been shown to predict the likelihood of
chemotherapy benefit as well as recurrence in early-stage breast
cancer. In addition to this widely adopted test, Genomic
Health provides the Oncotype DX colon cancer test, the first
multigene expression test developed for the assessment of risk of
recurrence in patients with stage II disease. As of March 31,
2011, more than 10,000 physicians in over 60 countries had ordered
more than 200,000 Oncotype DX tests. Genomic Health
has a robust pipeline focused on developing tests to optimize the